Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS203 + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JS203 + gemcitabine + oxaliplatin is a combination therapy regimen being developed by Shanghai Junshi Bioscience for the treatment of various B-cell non-Hodgkin lymphomas. The regimen combines JS203, a recombinant humanized bispecific antibody targeting CD20 and CD3, with the standard Gemox chemotherapy backbone (gemcitabine and oxaliplatin). JS203 functions as a T-cell engager, binding to CD20 on malignant B-cells and CD3 on T-cells to induce T-cell activation and directed cytotoxicity against the tumor cells. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis, while oxaliplatin is a platinum-based agent that causes DNA cross-linking and apoptosis. This combination is currently being evaluated in Phase 2 clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL).
- Other names
- JS203 + Gemox
02
Targets
DNACD20 (B-lymphocyte antigen CD20)RNR (Ribonucleotide reductase)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on JS203 + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS203 + gemcitabine + oxaliplatin.